Your browser doesn't support javascript.
loading
節目: 20 | 50 | 100
结果 1 - 3 de 3
过滤器
1.
China Pharmacist ; (12): 435-441, 2023.
文章 在 中文 | WPRIM | ID: wpr-1025900

摘要

Objective To investigate the effect of glucocorticoids on the prognosis and inflammatory markers of patients with acute severe pancreatitis(SAP).Methods A retrospective collection was performed for SAP patients diagnosed and treated in the Department of General Hepatobiliary Surgery,the Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from January 2020 to January 2023.SAP patients were divided into GC group and non-GC(NGC)group according to whether they used glucocorticoids(GC)or not.The two groups were compared with general data,inflammatory markers[neutrophil-lymphocyte ratio(NLR),monocyte-lymphocyte ratio(MLR),platelet-lymphocyte ratio(PLR),systemic inflammatory index(SII)and C-reactive protein-albumin ratio(CAR)],clinical events[continuous renal replacement therapy(CRRT),vasoactive drugs,ICU stay,total length of stay and survival)],and complications(organ failure,electrolyte imbalances,gastrointestinal bleeding and infection).Kaplan-Meier curve analysis of the relationship between GC and death in SAP patients.Logistic regression was used to explore the relationship between GC and death and organ failure.Results A total of 84 patients with SAP,40 in the GC group and 44 in the NGC group were included in the study.After treatment,NLR,MLR,PLR,SII and CAR in the GC group were significantly lower than those in the NGC group(P<0.05).There were no statistically significant differences between the GC and NGC groups in CRRT treatment,vasoactive drug use,surgery,ICU stay,total length of stay,electrolyte imbalance,gastrointestinal bleeding,pancreatic pseudocyst,abscess formation,pancreatic encephalopathy,and infectious complications(P>0.05);The mortality rate and organ failure incidence of patients in the GC group were significantly lower than those in the NGC group(P<0.05).The results of multivariate regression showed that the use of GC was an independent protective factor for death[OR=0.243,95% CI(0.062,0.948),P=0.042]and organ failure[OR=0.401,95% CI(0.165,0.976),P=0.044]in SAP patients.Conclusion GC can reduce the mortality rate and organ failure rate of SAP patients without increasing the incidence of additional complications,and has a high safety profile.

2.
文章 在 英语 | WPRIM | ID: wpr-921369

摘要

OBJECTIVES@#To compare the effects of different irradiators on the establishment of osteoradionecrosis of jaw model (ORNJ) to explore an ideal modeling method.@*METHODS@#A total of 33 adult SD rats were included and randomly divided into three groups according to the radiation equipment, namely, the blank control (CN, 3 rats), group A (linear accelerator irradiation, 15 rats), and group B (small-animal irradiator irradiation, 15 rats). Groups A and B were irradiated with daily fractions of 7, 8, and 9 Gy for 5 days and further divided into three subgroups as follows: group A@*RESULTS@#At 3 weeks after dental extractions, complete gingival healing was found in the regions of dental extractions in groups A@*CONCLUSIONS@#Small-animal irradiator irradiation is an ideal device for establishing ORNJ model.


Subject(s)
Animals , Rats , Mandible , Molar , Osteoradionecrosis/etiology , Rats, Sprague-Dawley , X-Ray Microtomography
3.
文章 在 中文 | WPRIM | ID: wpr-272469

摘要

Although the traditional chemotherapy has achieved a certain effect for patients with acute myeloid leukemia (AML), but there are still limitations in terms of improving the rate of complete remission and overcome relapse after remission. The further study found that many cytogenetic molecular and epigenetic abnormalities occurred during the progression of AML, such as abnormal expression of cell surface molecules, mutation, gene aberrant methylation and so on. The drugs targeted at these changes can improve the prognosis for patients, and provide a new way for treating patients with AML. At present, the mostly targeted drugs include monoclonal antibodies CD33-Ab, tyrosine kinase inhibitor, inhibitors of DNA methyltransferases inhibitors and so on. In this review, the progress of targeted therapy in AML treatment is summarized.


Subject(s)
Humans , Antibodies, Monoclonal , Therapeutic Uses , DNA Modification Methylases , Leukemia, Myeloid, Acute , Drug Therapy , Mutation , Prognosis , Protein Kinase Inhibitors , Therapeutic Uses , Remission Induction
搜索明细